Hormone Therapy Linked to Cognitive Decline

Area of Science:

• Oncology
• Neuroscience
• Endocrinology

Background:

• Early breast cancer treatment often involves endocrine therapy and sometimes chemotherapy.
• Cognitive dysfunction is a recognized side effect of cancer treatments.
• The specific impact of endocrine therapy on cognition in early breast cancer is not fully elucidated.

Purpose of the Study:

• To investigate the association between endocrine therapy and cognitive decline in early breast cancer patients.
• To determine if chemotherapy influences the relationship between endocrine therapy and cognitive function.
• To provide evidence-based recommendations for monitoring cognitive health in this patient population.

Main Methods:

• Analysis of a subgroup of patients from the TAILORx trial.
• Assessment of cognitive function in relation to endocrine therapy and chemotherapy exposure.
• Longitudinal evaluation of cognitive symptoms over the course of treatment.

Main Results:

• Endocrine therapy was associated with extended cognitive decline.
• This cognitive decline occurred irrespective of whether patients received initial chemotherapy.
• The findings highlight a potential neurotoxic effect of long-term hormone therapy.

Conclusions:

• Endocrine therapy may contribute to persistent cognitive impairment in early breast cancer survivors.
• Periodic cognitive assessments are crucial for women undergoing hormone therapy.
• Clinical monitoring should include evaluation for worsening cognitive symptoms during treatment.